Background {#Sec1}
==========

The glucocorticoid-induced leucine zipper (GILZ) protein is an intracellular protein that is induced by glucocorticoids. Recent studies have highlighted a major role of GILZ in the anti-inflammatory activities of glucocorticoids. GILZ inhibits the nuclear factor (NF)-kB pathway in human macrophage cells, epithelial respiratory cells and T lymphocytes \[[@CR1]--[@CR4]\]. GILZ also promotes T helper (Th)17 cell polarization toward a regulatory mesenchymal stem cell phenotype in arthritis \[[@CR5]\], and it even displays additional functions in depression \[[@CR6]\] and spermatogenesis \[[@CR7]\]. Further, GILZ is expressed by synovial fibroblasts and is an endogenous anti-inflammatory mediator in rheumatoid arthritis \[[@CR8]\]. Ngo et al*.* have reported the anti-inflammatory activity of exogenous GILZ in the treatment of collagen-induced arthritis \[[@CR9]\]. However, GILZ depletion does not always impair the anti-inflammatory activities of exogenous glucocorticoids \[[@CR9], [@CR10]\]. Thus, evidence of a central role of GILZ as an anti-inflammatory agent is lacking and controversial, and requires further exploration, specifically with respect to osteoarthritis (OA), for which intra-articular glucocorticoid injections are used as a symptomatic treatment.

OA is characterized by cartilage breakdown, subchondral bone thickening, osteophyte formation and synovial inflammation. It was first considered to be a degenerative disease caused by aging and mechanical stress. However, obesity has also been identified as a risk factor for digital OA \[[@CR11]\] (involving non-weight-bearing joints), suggesting a metabolic influence on OA pathogenesis \[[@CR12]\]. The metabolic origin of OA can be partly attributed to the presence of adipokines, such as leptin \[[@CR13]--[@CR15]\], which has a well-established link with OA. For example, the synovial and serum leptin levels have both been correlated with the radiologic score for OA severity \[[@CR14]\]; the leptin concentration in synovial fluid has been correlated with body mass index (BMI) \[[@CR16]\]; higher leptin expression has been detected in vitro in OA cartilage tissues compared with healthy control tissues \[[@CR13]\]; and obesity due to impaired leptin signaling in mice does not lead to OA, in contrast to what is observed in obesity due to overfeeding \[[@CR15]\].

In vitro*,* leptin has pro-inflammatory properties; e.g., it induces interleukin-6 (IL-6) expression in synovial fibroblasts \[[@CR17]\] and matrix metalloproteinase (MMP) production in human osteoarthritic cartilage \[[@CR18]\]. We have previously demonstrated that OA synovial fibroblasts spontaneously produce leptin in vitro \[[@CR19]\], suggesting their contribution to the intra-articular leptin level. Expression of leptin and its receptor (Ob-R) are strongly enhanced by glucocorticoids in OA synovial fibroblasts. Furthermore, we have previously demonstrated the involvement of transforming growth factor-β (TGF-β) signaling; prednisolone induces leptin secretion through the ALK1-Smad1/5 pathway, while TGF-β1 suppresses prednisolone-induced leptin secretion through ALK5-Smad2/3 \[[@CR20]\].

Glucocorticoids bind to their native receptor, glucocorticoid receptor (GR), and mediate their effects through two different pathways: the "trans-repression" and the "trans-activation" \[[@CR21]\]*.* Although this duality is more complex and although these two pathways are less separate than initially described, trans-repression is usually associated with anti-inflammatory effects, and trans-activation is typically correlated with adverse metabolic events. Selective glucocorticoid receptor agonists (SEGRAs) are GR agonists that are known to have a better benefit-risk ratio than glucocorticoids and do not induce adverse metabolic events. They only activate the trans-repression pathway without modulating trans-activation \[[@CR21]\]. We previously observed that SEGRA compound A (CpdA), which is known to have a better benefit-risk ratio than glucocorticoids \[[@CR22]\], does not induce leptin secretion or Ob-R expression \[[@CR23]\]. Therefore, regarding the detrimental role of leptin in OA, we hypothesized that leptin and Ob-R induction could result from glucocorticoid-associated adverse events. However, the underlying mechanisms remain to be elucidated, and the link between GILZ and leptin is unknown.

GR is the native receptor of glucocorticoids. However, glucocorticoids can also act through mineralocorticoid receptor (MR) \[[@CR24]\]. Conversely, mineralocorticoids act through GR \[[@CR25]\] in addition to their native receptor, MR. Recent studies have suggested that components of metabolic syndrome are associated with abnormal aldosterone physiology \[[@CR26]\]*.* Furthermore, leptin secretion is increased after aldosterone exposure in brown adipose tissue \[[@CR27]\]. Of interest, GILZ expression is also induced by mineralocorticoids, e.g.*,* its involvement in epithelial channel induction in the kidneys occurs through MR \[[@CR28]\].

Therefore, in the present study, we investigated the following issues: (1) whether GILZ expression is also induced by mineralocorticoids in human OA synovial fibroblasts and whether this effect is dependent on either GR or MR; (2) whether GILZ and leptin expression are closely correlated; and (3) whether GILZ plays a central role as an anti-inflammatory agent in this type of cell.

Methods {#Sec2}
=======

Human synovial fibroblasts and cell culturing {#Sec3}
---------------------------------------------

Synovial tissue was obtained from patients with OA during knee replacement surgery. All patients (n = 16) presented with symptomatic knee OA without inflammatory disease or cancer. None of the patients had received oral or intra-articular glucocorticoids for at least one year. The mean patient age was 71 (58--82) years, and the mean BMI was 26.3 (22.2--32.7) kg/m^2^. Seven patients were female (44 %).

Synovial fibroblasts were isolated as previously described \[[@CR19]\]. Cells were cultured in DMEM (Cambrex Bio Science, USA) with 10 % FBS (Lonza, Switzerland), L-glutamine (2 mM), streptomycin (100 mg/mL) and penicillin (100 U/mL) (BioWhittaker, USA). A total of 5 × 10^5^ synovial fibroblasts/well were plated in 24-well plates (BD Biosciences, USA). Cells were used at passages 3--7 and were stimulated with the glucocorticoid prednisolone (1 μM, unless stated otherwise), the mineralocorticoid aldosterone (1 and 10 μM, unless stated otherwise), the GR antagonist mifepristone (5 μM), the MR antagonist eplerenone (5 μM), the MR antagonist spironolactone (5 μM) (Sigma-Aldrich, USA), the SEGRA CpdA (1 and 10 μM) (Santa Cruz Biotechnology, USA), TGF-β1 (10 ng/mL) (Gibco-BRL, USA), tumor necrosis factor-α (TNF-α) (10 ng/mL) (Biosource, USA), and MG132 (10 μM) (Alexis Corporation, Switzerland). The proteasome inhibitor MG132 was added to the medium in the last 12 h to enhance GILZ visualization when GILZ was analyzed with western blot.

Transfection with lentiviruses expressing GILZ and GR small hairpin RNA (shRNA) {#Sec4}
-------------------------------------------------------------------------------

Lentiviral vectors were generated by co-transfecting Lenti-X 293 T cells (Clonetech, Belgium) with a pSPAX2 plasmid (Addgene, Plasmid \#12260), a VSV-G-encoding vector, a GILZ (TSC22D3) shRNA plasmid (\#TRCN0000013793 (GILZ shRNA1), \#TRCN0000364625 (GILZ shRNA2) or \#TRCN0000369187 (GILZ shRNA3), Sigma-Aldrich, USA), a GR (NR3C1) shRNA plasmid (\#TRCN0000245007 (GR shRNA1), \#TRCN0000245003 (GR shRNA2) or \#TRCN0000245004 (GR shRNA3), Sigma-Aldrich, USA), or a non-target sequence-encoding plasmid (Sigma, Belgium, SHC002). At 72 h post-transfection, viral supernatants were collected, filtered, and concentrated 100 × by ultracentrifugation. Lentiviral vectors were then titrated using a quantitative polymerase chain reaction (PCR) Lentivirus Titration (Titer) Kit (ABM, USA, LV900). A total of 5 × 10^5^ synovial fibroblasts/well were plated in 24-well plates (BD Biosciences, USA) and infected with lentiviruses at a multiplicity of infection (MOI) of 30, unless otherwise indicated. After 72 h of incubation, the medium was removed, and the cells were stimulated.

Enzyme-linked immunosorbent assay (ELISA) {#Sec5}
-----------------------------------------

A commercially available sandwich ELISA kit (R&D Systems, USA) was used to quantify leptin, IL-6, IL-8 and MMP-1 expression in the culture supernatants. All experiments were performed in triplicate.

Western blotting {#Sec6}
----------------

Total protein extracts were prepared as described previously \[[@CR19]\]. Ob-R (B-3) (sc-8391), GR (41) (sc-136209), GILZ (sc-33780) (Santa Cruz Biotechnology, USA), and glyceraldehyde 3-phosphate dehydrogenase (GAPDH) (Sigma-Aldrich, USA) primary antibodies were used. Western blots were visualized with an anti-mouse or anti-rabbit secondary antibody (Cell Signaling, USA) diluted 1/1000 and enhanced chemiluminescence reagents (GE Healthcare, UK). Western blot band quantification was performed with Image Studio Lite software (USA), and protein expression levels were normalized to the GAPDH level.

Quantitative reverse transcription PCR (RT-qPCR) {#Sec7}
------------------------------------------------

Total RNA was isolated from synovial fibroblasts (either untreated or treated with the indicated concentration of prednisolone or aldosterone for 5 days) and purified using a Nucleospin RNA Kit, with rDNAse included (\#740955,). Next, complementary DNA (Cdna) was synthesized by the reverse transcription of 1 μg RNA (in each reaction) with a RevertAid H Minus First Strand cDNA Synthesis Kit (\#K1632, Thermo Scientific, Belgium) according to the manufacturer's instructions. The resulting cDNA was subsequently PCR amplified with a KAPA SYBR FAST detection system (\#KK4611, Belgium). Real-time PCR was performed using a LightCycler 480 instrument (Roche, Belgium), and data were analyzed with LC480 software, release 1.5.0 SP4. cDNA dilution curves were generated for each gene and were used to calculate individual real-time PCR efficiencies (*E* = 10^\[−1/slope\]^). The 2^−ΔΔCT^ method was then used to calculate the relative gene expression levels between the untreated (calibrator sample) and treated synovial fibroblasts. Input amounts were normalized to the *β2-microglobulin* endogenous control gene. All primers were purchased from Eurogentec (Belgium). The following primer sequences were used: *leptin*, 5′- AACCCTGTGCGGATTCTTGT-3′ (forward) and 5′- TCTTGGACTTTTTGGATGGGC-3′ (reverse); *GILZ*, 5′-GCACAATTTCTCCATCTCCTTCTT-3′ (forward) and 5′- TCAGATGATTCTTCACCAGATCCA-3′ (reverse); *β2-microglobulin*, 5′-TTTCATCCATCCGACATTGA-3′ (forward) and 5′-CCAGTCCTTGCTGAAAGACA-3′ (reverse).

Statistical analysis {#Sec8}
--------------------

Log transformation was applied to all variables to normalize their distribution. Statistical analysis was performed using GraphPad Prism software (version 6) by one-way analysis of variance (ANOVA) for multiple comparisons, followed by Tukey's post hoc test. The results were considered significant at a *p* value \<0.05. Graphs were constructed using the mean ± standard deviation (SD) calculated from three or more independent experimental replicates for the ELISA, RT-qPCR and western blot experiments. Independent experiments were performed using synovial fibroblasts from different patients (n = 3 or more).

Results {#Sec9}
=======

Prednisolone and aldosterone induced GILZ protein expression through GR in human OA synovial fibroblasts {#Sec10}
--------------------------------------------------------------------------------------------------------

Human OA synovial fibroblasts were stimulated for 5 days with prednisolone (1 μM) (a glucocorticoid) or aldosterone (1 or 10 μM) (a mineralocorticoid). Western blotting (Fig. [1a](#Fig1){ref-type="fig"}) revealed that prednisolone and aldosterone induced GILZ expression in these cells.Fig. 1Glucocorticoid-induced leucine zipper (*GILZ*) expression is induced by prednisolone and aldosterone through glucocorticoid receptor (*GR*). **a** Human osteoarthritis (OA) synovial fibroblasts were pre-incubated or not for 1 h with a GR inhibitor (mifepristone) or mineralocorticoid receptor (*MR*) inhibitors (eplerenone and spironolactone) and were then stimulated for 5 days with a glucocorticoid (prednisolone) or a mineralocorticoid (aldosterone). GILZ and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts were analyzed by western blotting. *Right panels*, quantification results of western blots shown in *left panels*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 4 patients). Significance was set at *p* \< 0.05. *b*\*Significantly different from *a*; *c*\*significantly different from *b*; *d* not significantly different from *b*. **b**, **c** Synovial fibroblasts were infected with three different lentiviruses expressing GR shRNA or with a non-target control lentivirus and were stimulated or not for 5 days with prednisolone or aldosterone. A GR inhibitor (mifepristone) was used as a positive control for GR inactivation. GILZ, GR, and GAPDH expression in whole-cell extracts were analyzed by western blotting. *Right* (**b**) and *upper* (**c**) *panels*, quantification results of western blots shown in *left panels* and *lower panels*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 3 patients). Significance was set at *p* \< 0.05. *f*\*Significantly different from *e*; *h*\*significantly different from *g*; *i*\*significantly different from *h. kD* kiloDalton, *shRNA* short hairpin RNA

Glucocorticoids and mineralocorticoids have affinity for both GR and MR. Therefore, both receptors were investigated to determine which one is involved in GILZ expression. Cells were pre-incubated with a GR inhibitor (5 μM mifepristone) or MR inhibitor (5 μM eplerenone or 5 μM spironolactone) and were then stimulated for 5 days with prednisolone (1 μM) or aldosterone (1 or 10 μM). The GR inhibitor mifepristone strongly reduced both prednisolone- and aldosterone-induced GILZ protein expression (Fig. [1a](#Fig1){ref-type="fig"}). In contrast, the MR inhibitors eplerenone and spironolactone did not significantly modulate prednisolone-induced or aldosterone-induced GILZ expression in any experiments (Fig. [1a](#Fig1){ref-type="fig"}). These results suggest that mineralocorticoids and glucocorticoids induce GILZ expression through GR but not MR in OA synovial fibroblasts.

To further confirm the involvement of GR in prednisolone-induced and/or aldosterone-induced GILZ expression, we performed shRNA experiments to silence GR. Cells were infected with three different lentiviruses expressing GR shRNA or with a non-target control lentivirus. GR shRNA1, 2 and 3, but not the control shRNA, reduced endogenous GR expression (Fig. [1b](#Fig1){ref-type="fig"}). Two bands were observed: the antibody was raised against amino acids 176-289 of GR of human origin. It can therefore recognize both isoforms and probably other GRα transcript splice variants, which could explain the presence of two large bands. Prednisolone-induced and aldosterone-induced GILZ expression was reduced when GR was silenced (Fig. [1c](#Fig1){ref-type="fig"}). The GR antagonist mifepristone was used as a positive control to demonstrate GR inactivation. Thus, we confirmed that glucocorticoid-induced and mineralocorticoid-induced GILZ expression was GR-dependent by the silencing of GR.

Leptin and GILZ were similarly modulated; leptin secretion and Ob-R expression were induced by prednisolone and aldosterone through GR {#Sec11}
--------------------------------------------------------------------------------------------------------------------------------------

We have previously shown that glucocorticoids enhance leptin secretion and Ob-R expression in synovial fibroblasts (\[[@CR19]\] and Fig. [2a](#Fig2){ref-type="fig"}: b\* vs. a). Similar to prednisolone (Fig. [2a](#Fig2){ref-type="fig"}), the mineralocorticoid aldosterone also induced leptin secretion and Ob-R protein expression at 1 μM (Fig. [2b](#Fig2){ref-type="fig"}: b\* vs. a) and 10 μM (Fig. [2c](#Fig2){ref-type="fig"}: b\* vs. a). Moreover, using specific inhibitors (a GR inhibitor (mifepristone) and MR inhibitors (eplerenone and spironolactone)), we observed that the prednisolone-induced (Fig. [2a](#Fig2){ref-type="fig"}: c\* *vs.* b\*) and aldosterone-induced (Fig. [2b and c](#Fig2){ref-type="fig"}: c\* *vs.* b\*) leptin secretion and Ob-R expression were GR-dependent but not MR-dependent in all experiments, as observed with GILZ. These results suggest that aldosterone induces leptin secretion and Ob-R expression in OA synovial fibroblasts through GR but not MR, similar to glucocorticoids. The use of GR and MR antagonists did not modulate the endogenous level of leptin secretion or Ob-R expression. Human OA synovial fibroblasts were then infected with three different lentiviruses expressing GR shRNA or with a non-target control lentivirus. Prednisolone-induced and aldosterone-induced leptin secretion and Ob-R expression were abolished when GR was silenced (Fig. [3](#Fig3){ref-type="fig"})*,* confirming the involvement of GR signaling in the induction of these processes.Fig. 2Leptin secretion and leptin receptor (*Ob-R*) expression were induced by prednisolone and aldosterone through glucocorticoid receptor (GR) signaling. Human osteoarthritis (OA) synovial fibroblasts were pre-incubated or not for 1 h with a GR inhibitor (mifepristone) or mineralocorticoid receptor **(**MR) inhibitors (eplerenone and spironolactone) and were then stimulated for 5 days with a glucocorticoid (prednisolone) (**A**) or mineralocorticoid (aldosterone) (**B**, **C**). Leptin expression was measured in cell culture supernatants by ELISA. Ob-R and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts were analyzed by western blotting. *Upper panels* (*right*), quantification results of western blots shown in *bottom panels*. Proteins levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 3 or 4 patients). Significance set at *p* \< 0.05. *b*\*Significantly different from *a*; *c*\*significantly different from *b*; *d* not significantly different from *b. kD* kiloDalton Fig. 3Leptin secretion and leptin receptor (*Ob-R*) expression were induced by prednisolone and aldosterone through glucocorticoid receptor (GR) signaling. Synovial fibroblasts were infected with three different lentiviruses expressing GR short hairpin RNA (*shRNA*) or with a non-target control lentivirus and were stimulated for 5 days with prednisolone or aldosterone. The GR inhibitor mifepristone was used as a positive control for GR inhibition. Leptin expression was measured in the cell culture supernatants by ELISA. Ob-R and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression were analyzed in whole-cell extracts by western blotting. *Middle panel*, quantification results of western blots shown in the *lower panel*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 3 patients). Significance was set at *p* \< 0.05. *b*\*Significantly different from *a*; *c*\*significantly different from *b*\*. *kD* kiloDalton

The induction of leptin by prednisolone and aldosterone was dose-dependent (Fig. [4a and b](#Fig4){ref-type="fig"}). A dose response was observed not only for leptin secretion in the cell culture supernatant (as measured by ELISA) (Fig. [4a](#Fig4){ref-type="fig"}) but also for leptin messenger RNA (mRNA) expression (as measured by RT-qPCR) (Fig. [4b](#Fig4){ref-type="fig"}). The induction of leptin by prednisolone was significant at concentrations of equal to or greater than 10 nM or 1000 nM for ELISA or RT-qPCR, respectively. However, it was not significant at 100 nM or 10 nM for RT-qPCR; although the mean value was higher than that for the control, the variance was high. Leptin induction by aldosterone was significant at concentrations of 100 nM and 1000 nM for ELISA and RT-qPCR, respectively. The induction of Ob-R (Fig. [4c](#Fig4){ref-type="fig"}) and GILZ (Fig. [4c](#Fig4){ref-type="fig"} for western blot and Fig. [5](#Fig5){ref-type="fig"} for qRT-PCR) by prednisolone and aldosterone was also dose-dependent, with significant induction at a concentration equal to or greater than 100 nM.Fig. 4Leptin secretion and leptin receptor (*Ob-R*) and glucocorticoid-induced leucine zipper (*GILZ*) expression were dose-dependent. **a**, **b** Human osteoarthritis (OA) synovial fibroblasts were stimulated for 5 days with increasing concentrations of a glucocorticoid (prednisolone) or mineralocorticoid (aldosterone). Leptin secretion was measured in the cell culture supernatants by ELISA, and leptin messenger RNA (mRNA) expression was measured by RT-qPCR. Graphs represent mean +/- SD (n = 4 or 5 patients). Significance was set at *p* \< 0.05. *b*\*Significantly different from *a*; *c* not significantly different from *a*; *e*\*significantly different from *d*; *f* not significantly different from *d*. **c** Human OA synovial fibroblasts were stimulated for 5 days with increasing concentrations of a glucocorticoid (prednisolone) or mineralocorticoid (aldosterone). Ob-R, GILZ and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts were analyzed by western blotting. *Right panels*, quantification results of western blots shown in the *left panels*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 3 patients). Significance was set at *p* \< 0.05. *h*\*Significantly different from *g*; *i* not significantly different from *g* Fig. 5Glucocorticoid-induced leucine zipper (*GILZ*) expression under prednisolone and aldosterone stimulation was dose dependent. Human osteoarthritis (OA) synovial fibroblasts were stimulated for 5 days with increasing concentrations of a glucocorticoid (prednisolone) or mineralocorticoid (aldosterone). GILZ messenger RNA (mRNA) expression was measured by RT-qPCR. Graphs represent mean +/- SD (n = 4 patients). Significance was set at *p* \< 0.05. *b*\*Significantly different from *a*; *c* not significantly different from *a*

TGF-β did not induce GILZ expression, and it decreased prednisolone-induced GILZ expression (Fig. [6a](#Fig6){ref-type="fig"}), which is in accordance with our previous results demonstrating that TGF-β does not induce leptin secretion and that it decreases glucocorticoid-induced leptin secretion \[[@CR20]\]. Moreover, the selective GR agonist CpdA, which does not induce leptin expression \[[@CR23]\], also does not induce GILZ expression (Fig. [6b](#Fig6){ref-type="fig"}). Taken together, these results indicate that leptin and GILZ have similar expression profiles, suggesting correlation between their expression.Fig. 6Transforming growth factor-β (*TGF-β*) decreased both prednisolone-induced leptin secretion and glucocorticoid-induced leucine zipper (*GILZ*) expression; Compound A (*CpdA*) did not induce GILZ expression. Human osteoarthritis (OA) synovial fibroblasts were stimulated for 5 days with prednisolone, TGF-β (**A**), or CpdA (**B**). Leptin expression was measured in the cell culture supernatants by ELISA. GILZ and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts was analyzed by western blotting. *Right panels*, quantification results of western blots shown in the *left panels*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 3 patients). *b*\*Significantly different from *a*; *c*\*significantly different from *b*; e\*significantly different from *d*; *f* not significantly different from *d*

GILZ was involved in prednisolone-induced and aldosterone-induced leptin and Ob-R expression {#Sec12}
--------------------------------------------------------------------------------------------

ShRNA experiments for the silencing of GILZ expression were performed to determine whether GILZ is involved in prednisolone- and/or aldosterone-induced leptin secretion. Human OA synovial fibroblasts were infected with three different lentiviruses expressing GILZ shRNA or with a non-target control lentivirus. After 72 h of incubation, the medium was removed, and the cells were stimulated with prednisolone (1 μM) or aldosterone (1 or 10 μM). GILZ shRNA reduced GILZ expression following prednisolone (Fig. [7a](#Fig7){ref-type="fig"}) or aldosterone (Fig. [7b](#Fig7){ref-type="fig"}) stimulation. Downregulation of GILZ expression resulted in significant decreases in prednisolone-induced (Fig. [7a](#Fig7){ref-type="fig"}) and aldosterone-induced (Fig. [7b](#Fig7){ref-type="fig"}) leptin and Ob-R expression compared with the controls. These decreases were correlated with the shRNA MOI and with the degree of GILZ silencing (Fig. [7c](#Fig7){ref-type="fig"}). GILZ silencing did not alter GR expression or prednisolone-induced GR degradation (Fig. [8](#Fig8){ref-type="fig"}).Fig. 7Glucocorticoid-induced leucine zipper (*GILZ*) silencing inhibited glucocorticoid-induced and mineralocorticoid-induced leptin and leptin receptor (*Ob-R*) expression. Human osteoarthritis (OA) synovial fibroblasts were infected with three different lentiviruses expressing GILZ short hairpin RNA (*shRNA*) or with a control lentivirus (multiplicity of infection (MOI) 30 for **a** and **b**; MOI 5, 10 and 20 for **c**). After 72 h, the cells were stimulated for 5 days with a glucocorticoid (1 μM prednisolone) or mineralocorticoid (10 μM aldosterone). Leptin expression was measured in the cell culture supernatants by ELISA. Ob-R, GILZ and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts was analyzed by western blotting. *Right panels*, quantification results of western blots shown in the *left panels*. Protein levels were normalized to GAPDH. Graphs represent mean +/- SD (n = 5 patients). *b*\*Significantly different from *a*; *c*\*significantly different from *b. kD* kiloDalton Fig. 8Glucocorticoid-induced leucine zipper (GILZ) silencing did not alter prednisolone-induced glucocorticoid receptor (*GR*) degradation. Human osteoarthritis (OA) synovial fibroblasts were infected with a lentivirus expressing GILZ short hairpin RNA (*shRNA*) or with a control lentivirus. After 72 h, the cells were stimulated for 1, 4, 6, or 12 h with a glucocorticoid (1 μM prednisolone). Leptin expression was measured in the cell culture supernatants by ELISA. GILZ and glyceraldehyde 3-phosphate dehydrogenase (*GAPDH*) expression in whole-cell extracts was analyzed by western blotting. *Upper panel*, quantification results of western blot shown in the *lower panel*. Protein levels were normalized to GAPDH. Graph represents mean +/- SD (n = 3) patients. *kD* kiloDalton

GILZ inhibition did not alter the anti-inflammatory properties of prednisolone {#Sec13}
------------------------------------------------------------------------------

Synovial fibroblasts spontaneously produced the pro-inflammatory cytokines IL-6, IL-8 and MMP-1, and cell stimulation by TNF-α enhanced the secretion of these cytokines (Fig. [9a-c](#Fig9){ref-type="fig"}). Human OA synovial fibroblasts were infected with three different lentiviruses expressing GILZ shRNA or with a non-target control lentivirus. Cells were pre-incubated (Fig. [9d-f](#Fig9){ref-type="fig"}) or not (Fig. [9a-c](#Fig9){ref-type="fig"}) for 1 h with prednisolone (1 μM) and were then stimulated or not with TNF-α (10 ng/mL) for 12 h. GILZ-shRNA did not significantly alter TNF-α-induced IL-6, IL-8 and MMP-1 production (Fig. [9a-c](#Fig9){ref-type="fig"}). Moreover, GILZ inhibition did not alter the capacity for prednisolone to reduce the TNF-α-induced production of these cytokines (Fig. [9d-f](#Fig9){ref-type="fig"}). These results suggest that GILZ is not an essential mediator of the anti-inflammatory activities of glucocorticoids in OA synovial fibroblasts.Fig. 9Glucocorticoid-induced leucine zipper (*GILZ*) inhibition did not alter the capacity for prednisolone to reduce IL-6, IL-8 and matrix metalloproteinase-1 (*MMP-1*) production. Human osteoarthritis (OA) synovial fibroblasts were infected with three different lentiviruses expressing GILZ short hairpin RNA (*shRNA*) or with a control lentivirus (one sample was infected with one shRNA and the three results were pooled). Cells were pre-incubated (**D**, **E**, **F**) or not (**A**, **B**, **C**) for 1 h with prednisolone (1 μM) and were then stimulated or not with TNF-α (10 ng/mL) for 12 h. The IL-6, IL-8 and MMP-1 levels in the cell culture supernatants were measured by ELISA. Graphs represent mean +/- SD (n = 3 patients). Fold reductions in IL-6, IL-8, and MMP-1 induced by TNF-α were measured by comparing the levels in the presence or not of prednisolone (1 μM). *b*\*Significantly different from *a*; *c* not significantly different from *b*; *e f* not significantly different from *d*

Discussion {#Sec14}
==========

Glucocorticoids are widely used by rheumatologists, either to treat a flare in inflammatory rheumatic diseases or to reduce pain and swelling through intra-articular injection into joints in OA \[[@CR29]\]. Unfortunately, they also contribute to adverse events, such as diabetes mellitus and osteoporosis. Moreover, glucocorticoids enhance a catabolic reaction leading to the degradation of cartilage \[[@CR30]\], and they suppress matrix protein markers of chondrogenic differentiation \[[@CR31]\].

GILZ is an intracellular protein induced by glucocorticoids and is mainly present in immune cells \[[@CR32]--[@CR34]\]*.* It can also be induced by mineralocorticoids, as observed in kidney cells \[[@CR28]\]. Beaulieu et al. have observed GILZ expression in the synovium of patients with rheumatoid arthritis and in cultured rheumatoid arthritis synovial fibroblasts and have found that its expression is enhanced by dexamethasone and significantly reduced by mifepristone, suggestive of GR involvement \[[@CR8]\]. Our work extends the presence of GILZ to human OA synovial fibroblasts and demonstrates for the first time that both the glucocorticoid prednisolone and the mineralocorticoid aldosterone induce GILZ expression in these cells in a dose-dependent and GR-dependent process, at the protein and the mRNA level.

We propose a novel role of GILZ in contributing to corticoid-induced leptin and Ob-R expression in OA synovial fibroblasts. Indeed, we have previously reported that human OA synovial fibroblasts produce leptin (a pro-inflammatory adipokine involved in OA pathogenesis) and its receptor, Ob-R, both spontaneously and after stimulation with glucocorticoids \[[@CR19]\]. We have also previously demonstrated that leptin induction occurs independently of any adipogenesis-related processes by performing oil red staining and that it occurs in the absence of adipogenic mediators \[[@CR19]\]. Among adipokines, leptin is of particular interest in metabolic OA, as we did not detect any endogenous or glucocorticoid-induced secretion of resistin or adiponectin in OA synovial fibroblasts \[[@CR23]\]. The deleterious contribution of leptin to the pathogenesis of metabolic OA \[[@CR15]\] indicates that leptin and Ob-R expression in synovial fibroblasts contribute to the adverse metabolic events caused by glucocorticoids. GILZ, leptin and Ob-R protein expression are closely correlated, as demonstrated by the significant reductions in leptin and Ob-R expression following GILZ silencing.

Moreover, we previously reported that TGF-β reduced the prednisolone-induced leptin secretion through ALK5-Smad2/3 \[[@CR20]\]. In this work, we observed that TGF-β did not induce GILZ and reduced the prednisolone-induced GILZ expression, which is coherent with our previous results. This is also coherent with previous works in human bronchial epithelial cells, where TGF-β1 impaired the glucocorticoid trans-activation, did not induce GILZ mRNA and even reduced dexamethasone-induced GILZ expression also through ALK5-Smad2/3 \[[@CR35]\].

GILZ is primarily described as a mediator of the anti-inflammatory activities of glucocorticoids in immune-related cells \[[@CR32]--[@CR34]\]. GILZ overexpression has significant anti-inflammatory effects in the treatment of collagen-induced arthritis \[[@CR9], [@CR10]\]. However, in the current study, GILZ depletion in OA synovial fibroblasts did not alter either the TNF-α-induced pro-inflammatory protein levels (IL-6, IL-8, and MMP-1) or the capacity for glucocorticoids to downregulate the TNF-α-induced production of IL-6, IL-8, and MMP-1, supporting the notion that GILZ is not significantly involved in the anti-inflammatory regulation of glucocorticoids in OA. GILZ downregulation did not modulate GR expression or GR downregulation. A lack of inflammatory modulation in synovial cells following GILZ downregulation has also been reported in mouse models of collagen-induced arthritis \[[@CR9]\] and in human umbilical venous endothelial cells \[[@CR10]\]*.* Last, although Beaulieu et al. \[[@CR8]\] have previously shown that GILZ overexpression significantly inhibits the production of key pro-inflammatory cytokines, such as IL-6 and IL-8, in rheumatoid arthritis synovial fibroblasts, it has no effect on a panel of additional pro-inflammatory cytokines, such as IL-1β, TNF-α, and IL-12p70, which are produced by the same cells. Thus, involvement of GILZ in the inflammatory process appears to be cell-dependent.

In this study, we showed that the SEGRA CpdA (which activates only the trans-repression pathway and has a better benefit-risk ratio than glucocorticoids \[[@CR22]\]) did not induce GILZ expression. This finding is consistent with our previous study showing that CpdA does not induce leptin secretion or Ob-R expression and that it exhibits similar anti-inflammatory effects to classical glucocorticoids \[[@CR23]\], positioning the leptin secretion in the trans-activation pathway. While GILZ is not necessary for the glucocorticoid anti-inflammatory effect and is involved in leptin secretion, absence of GILZ induction by CpdA seems coherent. This result is also in agreement with Drebert et al., who have demonstrated a lack of GILZ induction under CpdA treatment in colon-cancer-derived myofibroblasts \[[@CR36]\] and with Gavrila et al. using airway smooth muscle cells \[[@CR37]\]. Moreover, other authors have demonstrated that CpdA does not induced DUSP1, which is another actor in the glucocorticoid trans-activation \[[@CR38]\].

From a metabolic point of view, it can be hypothesized that GILZ induction is deleterious in OA because it induces the adipokine leptin. Additional examples of the involvement of GILZ in glucocorticoid-associated adverse events have been reported. Dexamethasone and GILZ have been shown to inhibit the repair of respiratory epithelial cells \[[@CR39]\]. In addition, the long-term use of glucocorticoids has been demonstrated to have anti-myogenic effects due to the presence of GILZ as an effector \[[@CR40]\].

In the present study, aldosterone, a mineralocorticoid, was also found to be a significant stimulator of GILZ, leptin, and Ob-R expressions. These results are in accordance with those of previous studies showing an in vitro increase in the leptin mRNA level in brown adipose tissue after aldosterone exposure \[[@CR27]\] and higher circulating leptin levels in patients with primary hyperaldosteronism \[[@CR41]\]. Aldosterone is known for its association with a bad metabolic profile (i.e., its association with the development of metabolic syndrome in humans) \[[@CR42], [@CR43]\] and for its aggravation of glucose intolerance by high fructose in rats \[[@CR44]\]. It is also present in the synovial fluid of patients with OA \[[@CR45]\]. Therefore, targeting the aldosterone pathway could be promising for the treatment of OA.

Corticoid concentrations in synovial fluid have not been well-described. With regard to glucocorticoids, human OA synovial fluid has been reported to contain 125 nM cortisol \[[@CR45]\]. Significant induction of leptin, Ob-R, and GILZ expression has been observed at this concentration by prednisolone (a synthetic cortisol compound). Accordingly, the significant effect of glucocorticoids on leptin production in the joints in OA may be clinically relevant, even in the absence of exogenous glucocorticoid administration. However, the mineralocorticoid levels are 1000-fold decreased in biologic fluids compared to the glucocorticoid levels. Although 1 μM aldosterone has been used in studies with mechanistic models \[[@CR25]\], the physiological concentration is approximately 100 pM in OA synovial fluid \[[@CR45]\], which was not sufficient to induce leptin or Ob-R expression in our model. Therefore, we cannot affirm that leptin and GILZ induction by aldosterone is clinically relevant. However, the use of 1 μM and 10 μM aldosterone in the current study confirmed the focus of our mechanistic model on the role of GILZ in leptin expression.

The influence of aldosterone on GILZ, leptin and Ob-R expressions is also GR-dependent; indeed, their induction remains unchanged in the presence of specific MR inhibitors, whereas it is abolished in the presence of specific GR inhibitors or after GR silencing. Lee et al. have observed that GR silencing blocks leptin induction by cortisol in human adipocytes, in contrast with MR silencing \[[@CR46]\]*.* Leminen et al. have demonstrated in vivo downregulation of the expression of circulating leptin in humans with the GR inhibitor mifepristone \[[@CR47]\]. However, the regulation of leptin by aldosterone appears to be tissue-dependent, and it requires further clarification. In mice with impaired leptin receptor signaling, MR blockade by eplerenone administration in vivo has been shown to reduce leptin mRNA expression in retroperitoneal adipose tissue \[[@CR48]\].

Conclusion {#Sec15}
==========

In conclusion, we describe a new role for GILZ in the corticoid-induced leptin and Ob-R expression in OA synovial fibroblasts. Absence of GILZ prevents corticoid-induced leptin secretion and Ob-R expression without modulating the anti-inflammatory properties of glucocorticoids in OA synovial fibroblasts (Fig. [10](#Fig10){ref-type="fig"}). Regarding the deleterious involvement of leptin in OA pathogenesis, the use of GR agonists that do not activate GILZ pathways when using glucocorticoids should be evaluated.Fig. 10Absence of glucocorticoid-induced leucine zipper (*GILZ*) prevented the corticoid-induced leptin and leptin receptor (*Ob-R*) expression without modulating the anti-inflammatory properties of glucocorticoids. Prednisolone and aldosterone induced GILZ expression in OA synovial fibroblasts through glucocorticoid receptor (*GR*) but not mineralocorticoid receptor (*MR*) activation, whereas Compound A (*CpdA*) did not. Similar effects on leptin secretion and Ob-R expression were observed. Thus, GILZ was involved in prednisolone-induced and aldosterone-induced leptin secretion and Ob-R expression. In addition, GILZ inhibition did not alter the anti-inflammatory action of prednisolone
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